GT200100170A - Compuestos con nucleos heterocicliclo-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion delasproteinas quinasas y los metodos para su uso. - Google Patents

Compuestos con nucleos heterocicliclo-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion delasproteinas quinasas y los metodos para su uso.

Info

Publication number
GT200100170A
GT200100170A GT200100170A GT200100170A GT200100170A GT 200100170 A GT200100170 A GT 200100170A GT 200100170 A GT200100170 A GT 200100170A GT 200100170 A GT200100170 A GT 200100170A GT 200100170 A GT200100170 A GT 200100170A
Authority
GT
Guatemala
Prior art keywords
compounds
nuclees
methods
pharmaceutical compositions
kinase
Prior art date
Application number
GT200100170A
Other languages
English (en)
Inventor
Wesley Kwan Mung Chong
Rohit Kumar Duvadie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100170A publication Critical patent/GT200100170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS CON NUCLEOS HETEROCICLICOSHIDROXIIMINOFLUORENO QUE MODULAN Y/O INHIBEN LA ACTIVIDAD DE LAS PROTEINAS QUINASAS. ESTOS COMPUESTOS Y LAS COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SON CAPACES DE MEDIAR LA TRANSDUCCION DE LA SEÑAL DE LA TIROSINA CINASA PRA MODULAR Y/O INHIBIR LA PROLIFERACION DE LA CELULAS INDESEABLES. LA INVENCION TAMBIEN SE DIRIGE AL USO TERAPEUTICO O PROFILACTICO DE LAS COPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS Y A LOS METODOS, MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD EFICAZ DE DICHOS COMPUESTOS, PARA EL TRATAMIENTO DEL CANCER, Y LAS OTRAS ENFERMEDADES ASOCIADAS CON LA ANGIOGENESIS Y/O PROLIFERACION CELULAR INDESEABLE, TALES COMO LA RETINOPATIA DIABETICA, EL GLAUCOMA NEOVASCULAR, LA ARTRITIS REUMATOIDES Y LA SORIASIS. ESTOS COMPUESTOS ESTAN REPRESENTADOS POR LA FORMULA (I), EN DONDE R5, R6 Y X SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE.
GT200100170A 2000-08-18 2001-08-17 Compuestos con nucleos heterocicliclo-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion delasproteinas quinasas y los metodos para su uso. GT200100170A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22480500P 2000-08-18 2000-08-18

Publications (1)

Publication Number Publication Date
GT200100170A true GT200100170A (es) 2002-05-16

Family

ID=22842288

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100170A GT200100170A (es) 2000-08-18 2001-08-17 Compuestos con nucleos heterocicliclo-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion delasproteinas quinasas y los metodos para su uso.

Country Status (16)

Country Link
US (1) US6462060B2 (es)
EP (1) EP1309563B1 (es)
JP (1) JP2004506720A (es)
AR (1) AR032891A1 (es)
AT (1) ATE295354T1 (es)
AU (1) AU2001279090A1 (es)
BR (1) BR0113258A (es)
CA (1) CA2411924A1 (es)
DE (1) DE60110802T2 (es)
ES (1) ES2238463T3 (es)
GT (1) GT200100170A (es)
MX (1) MXPA03001452A (es)
PA (1) PA8525701A1 (es)
PE (1) PE20020289A1 (es)
SV (1) SV2003000603A (es)
WO (1) WO2002016326A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
WO2003061566A2 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
DE602004032370D1 (de) * 2003-10-16 2011-06-01 Imclone Llc Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
CA2583315A1 (en) * 2004-10-06 2006-06-01 Tiltan Pharma Ltd. Method and composition for enhancing anti-angiogenic therapy
DE602006018590D1 (de) 2005-03-29 2011-01-13 Icos Corp Heteroarylharnstoffderivate zur hemmung von chk1
WO2007026720A1 (ja) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
DE69532817T2 (de) 1994-11-10 2005-01-13 Millenium Pharmaceuticals, Inc., Cambridge Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
AU737073B2 (en) * 1996-05-30 2001-08-09 Aventisub Ii Inc. Alkyloxyamino substituted fluorenones and their use as protein kinase C inhibitors
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
JP2001518501A (ja) 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体
ID24372A (id) 1997-10-27 2000-07-13 Agouron Pharma SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs
ES2281941T3 (es) 1997-12-13 2007-10-01 Bristol-Myers Squibb Company Uso de pirazolo(3,4-b)piridina como inhibidores de quinasa dependiente de ciclina.
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
JP2002504553A (ja) 1998-02-26 2002-02-12 アベンティス・ファーマスーティカルズ・インコーポレイテツド ６，９−ジ置換２−［トランス−（４−アミノシクロヘキシル）アミノ］プリン
CN1297442A (zh) 1998-04-21 2001-05-30 杜邦药品公司 用作抗癌剂和抗增殖剂的5－氨基茚并[1,2－c]吡唑－4－酮类化合物
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
JP2002534058A (ja) * 1998-09-08 2002-10-15 アグロン ファ−マシュ−テイカルズ インコ−ポレイテッド 脈管内皮成長因子レセプタ一２タンパクの修飾方法およびその使用方法
BR9915132A (pt) * 1998-11-06 2001-08-07 Basf Ag Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica.

Also Published As

Publication number Publication date
JP2004506720A (ja) 2004-03-04
EP1309563B1 (en) 2005-05-11
US6462060B2 (en) 2002-10-08
BR0113258A (pt) 2003-07-15
SV2003000603A (es) 2003-01-13
PE20020289A1 (es) 2002-05-27
WO2002016326A1 (en) 2002-02-28
EP1309563A1 (en) 2003-05-14
AR032891A1 (es) 2003-12-03
AU2001279090A1 (en) 2002-03-04
MXPA03001452A (es) 2004-05-04
US20020049238A1 (en) 2002-04-25
CA2411924A1 (en) 2002-02-28
DE60110802T2 (de) 2005-10-06
ATE295354T1 (de) 2005-05-15
ES2238463T3 (es) 2005-09-01
DE60110802D1 (de) 2005-06-16
PA8525701A1 (es) 2002-04-25

Similar Documents

Publication Publication Date Title
GT200100014A (es) Compuestos de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo.
DOP2001000120A (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar e inhibir la proliferación celular
YU85601A (sh) Diaminotiazoli i njihova upotreba za inhibiranje proteinskih kinaza
UY28442A1 (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y métodos para intervenir en o inhibir la proliferacion celular
ME00385B (me) Jedinjenja indazola i farmaceutske kompozicije za inhibiranje protein kinaza i postupci za njihovu upotrebu
GT200400136A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular.
ECSP055858A (es) 2-(1h-indazol-6-ilamino)-compuestos benzamidas como inhibidores de la proteinquinasas útiles para el tratamiento de enfermedades oftálmicas
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
TWI262914B (en) Compounds and pharmaceutical compositions for inhibiting protein kinases
BRPI0412809A (pt) compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6
UY26877A1 (es) Compuestos pirazol-tiazol, composiciones farmacéuticas que los contienen, y su modo de empleo para inhibir quinasas ciclino- dependientes
GT200100170A (es) Compuestos con nucleos heterocicliclo-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion delasproteinas quinasas y los metodos para su uso.
UY26547A1 (es) Compuestos de amida y composiciones farmacéuticas para inhibir proteinquinasas, y su modo de empleo
UY26543A1 (es) Compuestos, composiciones farmacéuticas de indazol y métodos para mediar o inhibir la proliferación celular.
UY26667A1 (es) Compuestos, composiciones farmacéuticas y métodos para inhibir kinasas proteínicas
DOP2003000788A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso
ECSP003556A (es) Compuestos de indazole y composiciones farmaceuticas para la inhibicion de proteina kinasa y metodos para su uso